StockData

Fulgent Genetics vs Personalis

FLGT and PSNL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FLGT and PSNL compare

Personalis is the larger company, worth 2.4 times as much as Fulgent Genetics ($1.6B against $662M).

Fulgent Genetics grew revenue faster over the last twelve months (6.8% versus −13.3% for Personalis).

Fulgent Genetics keeps more of each dollar of sales as profit, with a net margin of −26.0% compared with −154% at Personalis.

Fulgent Genetics scores higher on the StockData Score (7 against 5 for Personalis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFLGTPSNL
Size and price
Market cap$662M$1.6B
Share price$24.07$14.80
Change, 1 year−18.6%94.7%
Change, 5 years−75.3%5.8%
Beta (5Y)0.501.24
Employees1,300260
StockData Score
Total score7 (better)5
Valuation score3 (better)0
Growth score00
Performance score1 (better)0
Health score35 (better)
Dividend score00
Valuation
P/S2.0× (better)22.7×
P/B0.7× (better)6.7×
FCF yield−15.7%−6.4% (better)
Fair value$45.46$3.33
Margin of safety47.0% (better)−344%
Growth
Revenue growth (TTM)6.8% (better)−13.3%
Revenue growth, 5Y average−5.2%−2.4% (better)
Profitability
Gross margin35.6% (better)12.7%
Operating margin−37.7% (better)−164%
Net margin−26.0% (better)−154%
FCF margin−32.0% (better)−145%
Return on equity−8.0% (better)−50.3%
Return on invested capital−10.9% (better)−450%
Financial health
Debt / equity0.00 (better)0.00
Interest coverage−1019.0×−536.7× (better)
Current ratio6.34 (better)5.28
Altman Z-score5.228.99 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield9.6% (better)−8.5%
Shareholder yield9.6% (better)−8.5%
Ownership
Held by institutions57.0%79.6%
Held by insiders39.5%15.0%
Insider net buying, 12 months−$286K (better)−$6.9M
Short interest, % of float12.1%7.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.